Injectable Naltrexone is Not a 1st Line Treatment for Most with OUD SSN (February 2023)
LONG-ACTING INJECTABLE NALTREXONE IS A SECOND-LINE TREATMENT FOR MOST INDIVIDUALS WITH MODERATE TO SEVERE OPIOID USE DISORDER.
Opioid Treatment Act of 2022 SSN Statement. (Feb 2022)
RESTRICTIONS ON DISPENSING METHADONE FOR TAKE-HOME USE SHOULD NOT BE CODIFIED IN STATUTE